| David Mckenzie Kraebber, MD | |
|
2421 Silver Stream Ln, Wilmington, NC 28401-7684 | |
| (910) 341-3300 | |
| (910) 251-8824 |
| Full Name | David Mckenzie Kraebber |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 43 Years |
| Location | 2421 Silver Stream Ln, Wilmington, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659372639 | NPI | - | NPPES |
| 1173584 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 201988 (Louisiana) | Secondary |
| 208800000X | Urology | 32526 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New Hanover Regional Medical Center | Wilmington, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wilmington Health Pllc | 6103722509 | 283 |
News Archive
ExonHit Therapeutics today announced that the Company was awarded two grants to support two of its Research & Development projects under the Qualifying Therapeutic Discovery Project Program: AclarusDx™ in Alzheimer's disease and the EHT 107 program in oncology.
Paratek Pharmaceuticals, Inc. has announced the dosing of the first patient in its Phase 3 clinical study of its lead drug candidate, omadacycline, for the treatment of Community Acquired Bacterial Pneumonia (CABP). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP.
Experiencing verbal abuse in childhood has a lasting negative effect on the course of bipolar disorder, researchers have found.
A new protocol for bone marrow transplants, which does not require the destruction of the recipient's immune system before transfer of the new bone marrow, is described by a group of Oxford scientists
New research funded by the National Cancer Institute (NCI) aims to boost understanding of how the immune system responds to COVID-19, from the start of infection to recovery.
› Verified 1 days ago
| Entity Name | Wilmington Health Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881632339 PECOS PAC ID: 6103722509 Enrollment ID: O20031208000800 |
News Archive
ExonHit Therapeutics today announced that the Company was awarded two grants to support two of its Research & Development projects under the Qualifying Therapeutic Discovery Project Program: AclarusDx™ in Alzheimer's disease and the EHT 107 program in oncology.
Paratek Pharmaceuticals, Inc. has announced the dosing of the first patient in its Phase 3 clinical study of its lead drug candidate, omadacycline, for the treatment of Community Acquired Bacterial Pneumonia (CABP). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP.
Experiencing verbal abuse in childhood has a lasting negative effect on the course of bipolar disorder, researchers have found.
A new protocol for bone marrow transplants, which does not require the destruction of the recipient's immune system before transfer of the new bone marrow, is described by a group of Oxford scientists
New research funded by the National Cancer Institute (NCI) aims to boost understanding of how the immune system responds to COVID-19, from the start of infection to recovery.
› Verified 1 days ago
| Entity Name | Vidant Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477648731 PECOS PAC ID: 0345343893 Enrollment ID: O20070321000445 |
News Archive
ExonHit Therapeutics today announced that the Company was awarded two grants to support two of its Research & Development projects under the Qualifying Therapeutic Discovery Project Program: AclarusDx™ in Alzheimer's disease and the EHT 107 program in oncology.
Paratek Pharmaceuticals, Inc. has announced the dosing of the first patient in its Phase 3 clinical study of its lead drug candidate, omadacycline, for the treatment of Community Acquired Bacterial Pneumonia (CABP). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP.
Experiencing verbal abuse in childhood has a lasting negative effect on the course of bipolar disorder, researchers have found.
A new protocol for bone marrow transplants, which does not require the destruction of the recipient's immune system before transfer of the new bone marrow, is described by a group of Oxford scientists
New research funded by the National Cancer Institute (NCI) aims to boost understanding of how the immune system responds to COVID-19, from the start of infection to recovery.
› Verified 1 days ago
| Entity Name | Vidant Medical Group Affiliates Llc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437549896 PECOS PAC ID: 5395066138 Enrollment ID: O20150605000882 |
News Archive
ExonHit Therapeutics today announced that the Company was awarded two grants to support two of its Research & Development projects under the Qualifying Therapeutic Discovery Project Program: AclarusDx™ in Alzheimer's disease and the EHT 107 program in oncology.
Paratek Pharmaceuticals, Inc. has announced the dosing of the first patient in its Phase 3 clinical study of its lead drug candidate, omadacycline, for the treatment of Community Acquired Bacterial Pneumonia (CABP). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP.
Experiencing verbal abuse in childhood has a lasting negative effect on the course of bipolar disorder, researchers have found.
A new protocol for bone marrow transplants, which does not require the destruction of the recipient's immune system before transfer of the new bone marrow, is described by a group of Oxford scientists
New research funded by the National Cancer Institute (NCI) aims to boost understanding of how the immune system responds to COVID-19, from the start of infection to recovery.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Mckenzie Kraebber, MD 1202 Medical Center Dr, Wilmington, NC 28401-7307 Ph: (910) 341-3300 | David Mckenzie Kraebber, MD 2421 Silver Stream Ln, Wilmington, NC 28401-7684 Ph: (910) 341-3300 |
News Archive
ExonHit Therapeutics today announced that the Company was awarded two grants to support two of its Research & Development projects under the Qualifying Therapeutic Discovery Project Program: AclarusDx™ in Alzheimer's disease and the EHT 107 program in oncology.
Paratek Pharmaceuticals, Inc. has announced the dosing of the first patient in its Phase 3 clinical study of its lead drug candidate, omadacycline, for the treatment of Community Acquired Bacterial Pneumonia (CABP). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP.
Experiencing verbal abuse in childhood has a lasting negative effect on the course of bipolar disorder, researchers have found.
A new protocol for bone marrow transplants, which does not require the destruction of the recipient's immune system before transfer of the new bone marrow, is described by a group of Oxford scientists
New research funded by the National Cancer Institute (NCI) aims to boost understanding of how the immune system responds to COVID-19, from the start of infection to recovery.
› Verified 1 days ago
Victor E Abraham, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1099 Medical Center Dr, Ste 101, Wilmington, NC 28401 Phone: 910-254-9995 Fax: 910-254-9996 | |
Dr. Edward W Whitesides, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1905 Glen Meade Rd, Wilmington, NC 28403 Phone: 910-763-6251 Fax: 910-763-7408 | |
Kaitlin Ridder, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1905 Glen Meade Rd, Wilmington, NC 28403 Phone: 910-763-6251 Fax: 910-763-7408 | |
Mr. Eric Dustin Morgan, PA-C Urology Medicare: Accepting Medicare Assignments Practice Location: 1099 Medical Center Dr Ste 101, Wilmington, NC 28401 Phone: 910-854-9995 Fax: 910-254-9996 | |
Robert Todd Bennett, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1814 New Hanover Medical Park Dr, Wilmington, NC 28403 Phone: 910-662-8765 Fax: 910-362-9123 | |
Anna Pieper Thompson, PA-C Urology Medicare: Accepting Medicare Assignments Practice Location: 1905 Glen Meade Rd, Wilmington, NC 28403 Phone: 910-421-2505 | |
Dr. Deborah Sperling Hess, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1202 Medical Center Dr, Wilmington, NC 28401 Phone: 910-341-3300 Fax: 910-251-2067 |